165 related articles for article (PubMed ID: 27622768)
1. The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
Neidhardt G; Becker A; Hauke J; Horváth J; Bogdanova Markov N; Heilmann-Heimbach S; Hellebrand H; Thiele H; Altmüller J; Nürnberg P; Meindl A; Rhiem K; Blümcke B; Wappenschmidt B; Schmutzler RK; Hahnen E
Eur J Cancer Prev; 2017 Mar; 26(2):165-169. PubMed ID: 27622768
[TBL] [Abstract][Full Text] [Related]
2. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
3. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
4. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
5. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
6. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
[TBL] [Abstract][Full Text] [Related]
7. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
8. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
9. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
10. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.
Zheng Y; Zhang J; Hope K; Niu Q; Huo D; Olopade OI
Breast Cancer Res Treat; 2010 Dec; 124(3):857-61. PubMed ID: 20697805
[TBL] [Abstract][Full Text] [Related]
11. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
12. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
13. RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.
Schnurbein G; Hauke J; Wappenschmidt B; Weber-Lassalle N; Engert S; Hellebrand H; Garbes L; Becker A; Neidhardt G; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2013 Dec; 15(6):R120. PubMed ID: 24359560
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Meindl A; Hellebrand H; Wiek C; Erven V; Wappenschmidt B; Niederacher D; Freund M; Lichtner P; Hartmann L; Schaal H; Ramser J; Honisch E; Kubisch C; Wichmann HE; Kast K; Deissler H; Engel C; Müller-Myhsok B; Neveling K; Kiechle M; Mathew CG; Schindler D; Schmutzler RK; Hanenberg H
Nat Genet; 2010 May; 42(5):410-4. PubMed ID: 20400964
[TBL] [Abstract][Full Text] [Related]
15. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in RAD51C in Jewish high cancer risk families.
Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
[TBL] [Abstract][Full Text] [Related]
17. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
18. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
20. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]